Synergy (SGYP) incurred R&D (research and development) expenses of ~$90 million, $78 million, and $ 83 million in fiscal 2016, 2015, and 2014, respectively.
AstraZeneca’s (AZN) recent product developments include four drugs that have recently received approvals from regulatory authorities. Four other drugs have received regulatory designations.
In this part, we’ll look at some of AstraZeneca’s corporate developments. It entered into some collaborative agreements in 1Q16, including drug development and commercialization rights.
Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.
Celldex rose by 12.3%. This is the second consecutive trading session the stock gained after it presented varlilumab data at the SITC Annual Meeting 2015.
The top ten small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the IBB and the SPDR S&P 500 ETF (SPY) with an average return of 6.25%.
Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.
